DT Cloud Star Acquisition Corp

This departure reduces the board's size ahead of the scheduled redemption window without identifying a successor, which may affect quorum availability and sponsor oversight while the SPAC remains in SEARCHING status. By explicitly attributing the exit to zero disagreement, the company aims to neutralize investor speculation concerning governance disputes, executive instability, or impending trust account erosion. The filing contains no disclosures regarding target acquisition progress, business combination negotiations, extension voting procedures, or the per-share trust balance, leaving all associated mechanics unchanged from prior filings.

A sustained deficiency below the 400-public-holder floor exposes the issuer to delisting, which historically compresses liquidity, elevates compliance costs, and disrupts the capital markets infrastructure required to close a business combination before the existing redemption deadline. Without an accepted curing plan by May 21, 2026, or a secured 180-day extension, forced relocation to a less liquid venue or mandatory dissolution could immediately impair investor exit pathways and alter the economics tied to the prevailing trust reserve per share.

For investors tracking redemption deadlines and deal progress, this filing confirms DT Cloud Star has a signed target — PrimeGen US, Inc. — with a stated Purchase Price of $1,489,800,000 before warrant/option adjustments, plus a non-redemption warrant mechanism for 1,931,900 shares intended to reduce redemptions. But the deal remains subject to shareholder approval and customary closing conditions, and the company has already absorbed heavy redemptions, leaving the trust at $17,876,466 across 1,652,509 redeemable shares at $10.82 per share as of year-end. Liquidity is extremely tight outside trust, and the company warns it may liquidate if no business combination closes by October 26, 2026 unless further extended. The BCA, redemption dynamics, sponsor extension financing, and going concern are the key items to watch.

The filing directly overhauls the redemption and liquidation calendar, collapsing the remaining execution window to roughly ten days before the March 26, 2026 cutoff. This compression forces immediate shareholder decisions regarding redemption versus continued trust exposure. The $150,000 contribution mechanically increases the aggregate trust balance, confirming sponsor continuation funding. However, the administrative delay in publishing the extension—filing the report eight days after the new deadline had already commenced—signals acute operational constraints and suggests management is either racing to finalize a deal under duress or preparing for rapid trust wind-down, heavily weighting near-term valuation and settlement risk.

Schedule 13G/A amendments allow investors to track institutional equity positioning relative to a SPAC’s search window and potential shareholder actions, yet because Barclays PLC did not attach numerical holdings or strategic declarations in the excerpt, the filing yields no direct guidance on redemption thresholds, trust maintenance, or deal execution timelines.

This filing moves DTSQ from a searching SPAC to a definitive deal stage. Investors should monitor: (a) redemption levels – the non-redemption warrants are designed to incentivize shareholders not to redeem, but high redemptions could reduce trust cash available for working capital. (b) The trust per share is $11.15, so redeeming shareholders get that amount. (c) The transaction must close by October 26,2026 or be extended. (d) The combined company will be a biotechnology firm focused on stem cell therapies and exosome products, with an FDA pre-IND meeting (PTS#PS009936) for a cell therapy candidate for acute alcoholic hepatitis. (e) Sponsor conduct: sponsor has agreed not to redeem and will receive a $2.5 million closing payment in exchange for 250,000 shares. (f) The registration statement (S-4) will follow, triggering a shareholder vote and redemption opportunity.

Establishes a definitive path to a business combination, sets the valuation and terms for PrimeGen, and provides a timeline for shareholder vote and closing. The non-redemption warrant structure incentivizes shareholders not to redeem. The trust per share is significantly below the stated $11.15, which may affect redemption decisions.

Strategy and corporate direction: PrimeGen US intends to use public market proceeds to advance clinical development, regulatory activities, and potential commercialization of its lead programs. Co-CEO Daniel Chiu stated the transaction will enhance capital access to support continued stem cell and exosome program development. Co-CEO Wai Szeto asserted the company's 'Triple Activated Mesenchymal Stem Cells (MSCs)' platform is differentiated and well positioned for next-stage advancement. DTCS Chairman and CEO Sam Zheng Sun claimed the combined entity will successfully capture large unmet market opportunities in regenerative medicine. Technology and pipeline milestones: PrimeGen US leverages nearly two decades of proprietary stem cell research to develop cell-based treatments for acute liver injury. The press release reports preclinical activity demonstrated in animal studies and completion of a Pre-Investigational New Drug application (Pre-IND) meeting with the FDA for Acute Alcoholic Hepatitis on December 17, 2025. Commercial valuation: The transaction implies an equity value for PrimeGen US of approximately $1.5 billion. Risk exposure: The document highlights inherent uncertainty of clinical success, FDA approval delays, BIOSECURE Act compliance impacts on manufacturing supply chains, intellectual property protection challenges, and funding availability for continued research and development.

This announcement triggers the proxy solicitation and registration statement process, dictating future redemption calendar dates and shareholder voting timelines. According to Co-CEOs Daniel Chiu and Wai Szeto, the deal implies an equity value of approximately $1.5 billion for PrimeGen US, which utilizes Triple Activated Mesenchymal Stem Cells targeting acute liver injury after completing an FDA Pre-IND meeting on December 17, 2025. Per the joint press release, forward-looking projections on clinical success, regulatory approval, and market capture carry explicit warnings about trial delays, BIOSECURE Act compliance, intellectual property protection, and potential additional capital raises, with final redemption and financing mechanics reserved for the upcoming S-4/DEFM14A filings.

A Nasdaq MVLS deficiency creates immediate structural risk to trading liquidity and exchange access before the SPAC’s combination deadline. Should the Company fail to demonstrate a sustained $50,000,000 market capitalization by July 14, 2026, delisting proceedings will likely suppress secondary-market pricing and increase transaction friction for shareholders attempting to exercise redemption rights or exit positions. Because the filing expressly omits any target update, trustee amendment, or extension proposal, capital deployment remains paused while the Company navigates exchange compliance, leaving shareholders exposed to prolonged search-period exposure and potential valuation compression independent of trust accruals.

The filing mechanically advances the company's redemption and liquidation deadline to January 26, 2026. It confirms the payment of the monthly extension fee and indicates management's intent to pursue a merger target instead of triggering an automatic liquidation. Chief Executive Officer Sam Zheng Sun signed the report, confirming administrative continuity.

The cancellation halts the immediate shareholder vote, meaning no business combination is advancing and the SPAC continues operating while retaining the reported $11.15 per share trust value. The original liquidation deadline of 2026-10-26 remains unchanged, keeping shareholders’ redemption options active and requiring the sponsor to convene future meetings for either an extension or a final deal vote. According to the press release, the firm is led by Chief Executive Officer Sam Zheng Sun and Chief Financial Officer Kenneth Lam, who state the company intends to restrict its initial business combination search to industries that complement their professional backgrounds.

This document materially recalibrates the economics of the SPAC’s search phase. By cutting the monthly sponsorship commitment in half compared to the initially projected $75,000, the board reduces near-term cash pressure while extending operational runway through October 26, 2026. The Company explicitly states the board believes this lower fee structure serves shareholder interests better than the previous cost basis. Conversely, the admission that trust balances may contract significantly upon redemption payouts underscores that post-extension liquidity will likely depend on external capital raising, which the Company cautions may be unavailable on acceptable terms. Because the extension requires a 65% vote, the dual proposals frame the December 22, 2025 meeting as a binary decision point: approve the reduced-fee extension and absorb diluted trust backing for continued deal pursuit, or reject it and trigger liquidation by December 26, 2025.

The one-week adjournment shifts the operative timeline for SPAC merger approvals and associated redemption windows. Investors tracking the redemption calendar must account for the revised 11:59 pm ET cutoff on December 21, 2025, for reversing redemptions or altering voting instructions. The filing cross-references the definitive proxy statement filed on December 2, 2025, indicating ongoing efforts to finalize a business combination. Sponsor activity is noted through the disclosure that Advantage Proxy, Inc. manages the solicitation and that Chief Executive Officer Sam Zheng Sun signed the filing. Shareholders are advised that no substantive amendments were made to the December 2 Proxy Statement or proxy card beyond this adjournment notice.

The adjournment extends the action window for redemption withdrawals and vote reversals while preserving the existing $11.15 trust per share and October 26, 2026 deadline. Because the December 15 gathering concluded without addressing the proposals referenced in the December 2 proxy statement, capital allocation and conversion timelines are deferred to the December 22 reconvening. The Company identifies Advantage Proxy, Inc. to assist with proxy solicitations, and Chief Executive Officer Sam Zheng Sun signed the report. No substantive claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel are disclosed beyond these procedural updates and standard regulatory disclosures.

The newly disclosed cutoff of December 26, 2025 directly recalibrates the operational timeline for any forthcoming redemption windows or mandatory liquidation events, requiring investors to adjust their holding periods accordingly. The confirmed deposit of $75,000 demonstrates continued sponsor financial commitment to preserving the SPAC vehicle, yet the company itself provides no substantiation regarding deal pipeline velocity, customer traction, revenue forecasts, market share claims, technology roadmaps, strategic alliances, or pending litigation. Because management attributes the extension solely to an administrative cash infusion rather than concrete transaction milestones, the material takeaway is mechanical: shareholders face an extended search horizon with preserved trust capital, but without verified deal certainty or updated strategic disclosures to justify retaining shares past the new December 26, 2025 expiration.

Lowering the extension fee to nil preserves trust capital for potential deal execution but triggers an immediate redemption election that will drain the trust account dollar-for-dollar for tendered shares, which the Board warns could leave only a small fraction of current funds remaining. Because the amendment requires the affirmative vote of sixty-five percent (65%) of outstanding shares and the sponsor controls only approximately 52.88%, the filing notes that insiders may purchase public shares in the open market or through negotiated private purchases to secure passage. The Board expressly states it provides no opinion on whether shareholders should redeem. Separately, management highlights a risk that the sponsor’s substantial ties to a non-U.S. person could subject future targets to CFIUS review, which the Company cautions could delay or block an acquisition. The proxy confirms the Company continues searching for a suitable target with no definitive agreements announced, and the sponsor has agreed to indemnify the trust to ensure public shareholders do not receive less than $10.00 per share in liquidation if third-party claims exhaust the account without executing waivers.

The board states the zero-fee extension provides financial flexibility to pursue high-quality targets without pressure from mounting extension costs, though heavy redemptions could deplete capital needed to close a deal. Public shareholders face a liquidity decision between locking in a pre-meeting payout at the undetermined trust-per-share value or retaining exposure to a zero-fee extension through October 26, 2026. The filing identifies five percent plus holders including Mizuho Financial Group (9.0 percent, 800,000 shares), Ramya Rao (6.2 percent, 700,000 shares), Westchester Capital Management (6.96 percent, 606,893 shares), Hudson Bay Capital Management (6.1 percent, 546,000 shares), Wolverine Asset Management (6.0 percent, 537,949 shares), and Goldman Sachs (6.0 percent, 536,967 shares). Named directors and executive officers include Sam Zheng Sun, Kenneth Lam, Jiayi Liang, Shaoke Li, Longjiao Li, and Chi Zhang. The company's retained proxy solicitor, Advantage Proxy, Inc., will receive $8,500 plus expenses. Additionally, the risk factors warn that because the company is incorporated in the Cayman Islands and headquartered in New York, it may trigger CFIUS review for national security concerns, which could delay or prevent a business combination and force liquidation.

The trust value per share continues to accrue interest, providing a modest premium above the $10.00 IPO price for redeeming shareholders. The extension to October 2026 reduces near-term liquidation risk but requires ongoing sponsor support ($75,000/month). The Company's low cash and negative working capital heighten going-concern risk if no deal is reached. The sponsor's willingness to fund extensions signals continued commitment, but the absence of a definitive agreement keeps the SPAC in a high-risk 'searching' status.

The 5,297,491-share tender directly reduces the public share base, recalibrating the denominator for any future trust-value-per-share accounting and redemption pacing analysis. The mandated $75,000 monthly deposit obligation locks the sponsor into recurring cash contributions if the full twelve-month extension corridor is utilized, demonstrating continued financial backing absent a near-term consummation. The October 26, 2026 deadline formally resets the liquidation horizon, extending the window for retail and institutional holders before potential delisting or liquidation triggers. Outside of these structural and governance updates, the filing contains no material disclosures regarding customer contracts, revenue trajectories, addressable market sizing, proprietary technology, third-party partnerships, or pending litigation. Management attributes the extension request solely to the need for additional deal-sourcing time, with no accompanying forward-looking commercial strategy outlined in the submission.

The filing confirms DTSQ avoided immediate liquidation by extending its deadline one month to Nov. 26, 2025, with the ability to extend up to Oct. 26, 2026. The massive redemption of 5,297,491 shares (approx. 60% of the 8.9M outstanding) signals severe shareholder disapproval of the deal search track record or terms, leaving a depleted trust and a sponsor note that can convert at a discount. The trust per-share value remaining after these redemptions is uncertain; investors should monitor the per-share trust value post-redemption. The extension vote passed with 5,917,850 votes for, 2,106,336 against—barely meeting the required 65% threshold.

This disclosure mechanically secures 600,000 shares against redemption ahead of the extension vote, preserving liquidity in the trust account and influencing the net proceeds available to the combined enterprise post-merger. The transfer of 200,000 founder shares to a public holder increases circulating supply and dilution contingent on the merger closing, while the Most Favored Nation clause establishes a pricing ceiling for future non-redemption solicitations. Extending the termination window to October 26, 2026 delays the potential liquidation trigger and extends the period for trust interest accruals. The explicit representation that trust funds will not cover Inflation Reduction Act excise taxes protects the residual trust balance from regulatory penalties, directly supporting the stability of the per-share trust value as the extension deadline approaches.

This adjournment pauses the voting and redemption calendar, extending the window during which capital remains locked and shares stay outstanding ahead of the October 22, 2025 meeting. The company’s explicit permission to reverse redemption requests indicates active shareholder retention efforts. Beyond scheduling logistics, the filing contains zero claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. All procedural directives are attributed to the registrant and countersigned by Chief Executive Officer Sam Zheng Sun.

Advancing the meeting date delays the shareholder vote on the pending business combination, directly extending the window for redemption elections and preserving trust liquidity longer than originally scheduled. By mandating specific cutoff times for revoking votes and withdrawing redemptions through VStock Transfer, LLC, the sponsor actively manages anticipated cash outflows and ensures capital remains available for the proposed transaction. The exclusive focus on administrative scheduling and proxy administration, rather than operational or financial disclosures, confirms the sponsor’s conduct remains centered on securing approval for the merger referenced in the September 22 filing, materially impacting when investors must decide whether to remain in the trust or exit pre-liquidation.

What changed: This is a Form 8-K current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, containing Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing) and Item 9.01 (Financial Statements and Exhibits), accompanied by press release Exhibit 99.1 announcing a Nasdaq delist determination. Mechanics governing listing status, shareholder thresholds, and corporate timelines: On July 15, 2026, Nasdaq’s Listing Qualifications Staff delivered a Delist Determination Letter confirming the Company failed to regain compliance with Listing Rule 5450(b)(2)(A) after a 180-calendar-day cure window that expired on July 14, 2026. Nasdaq cited a measured Market Value of Listed Securities falling short of the required $50,0000,000 baseline recorded across the November 21, 2025 to January 6, 2026 reporting period. Separately, the Company forfeited an extension previously approved on May 29, 2026 to satisfy the minimum 400 total shareholders requirement under Listing Rule 5450(a)(2); the original October 5, 2026 compliance deadline is nullified per Listing Rule 5810(C)(4)(d)(2). Nasdaq directed that trading suspension occur at the open on July 24, 2026 unless an appeal is submitted by July 22, 2026. The Company filed a timely hearing request, which temporarily stays the suspension. A Form 25-NSE will be lodged with the SEC to remove the securities from listing and registration once the appeal period lapses. The filing does not alter the trust account balance, the unitholder redemption calendar, or the business combination expiration date. Why it matters: Substantive disclosures regarding strategy, leadership, and operational scope: Delisting terminates exchange trading for the ordinary shares, units, and rights, which typically accelerates SPAC dissolution mechanics or compels out-of-band liquidation negotiations outside Nasdaq’s administrative framework. According to the press release dated July 20, 2026, the Company characterizes itself as a newly organized Cayman Islands blank check entity formed exclusively to pursue a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or analogous business combination, stating an intent to focus its target search on industries that complement its management team’s background. The release identifies Mr. Sam Zheng Sun as Chief Executive Officer, Mr. Kenneth Lam as Chief Financial Officer, and designates Sam Sun as the press contact at sam.sun@dstarspac.com. The filing discloses no operating revenue, existing customer relationships, proprietary technology, commercial partnerships, or litigation matters. All statements regarding Nasdaq rule compliance, the hearing request, and future business combination searches are attributed to the Company’s July 20, 2026 press release, which qualifies those projections with risks detailed in the Form 10-K filed March 25, 2026.

What changed: Amendment No. 1 to DT Cloud Star Acquisition Corporation's Form 10-K for fiscal 2025; the document carries no explanatory note saying what was amended and restates the annual report in full. It shows $17,876,466 held in trust at December 31, 2025 against $70,456,287 a year earlier, with public shares subject to redemption falling from 6,900,000 at $10.21 to 1,652,509 at $10.82. Cash was approximately $461 with a working capital deficit of about $361,245; net income was $2,132,715, driven by trust interest. Deferred underwriting compensation is $690,000. Why it matters: About 76% of the trust has already left through redemptions, so only 1,652,509 public shares remain and the $75,000 monthly extension deposit is spread across a shrinking base - each remaining share is being topped up more, hence the $10.82 redemption value. The hard deadline is October 26, 2026, after which an automatic winding up is triggered, and the auditor's report contains a going-concern explanatory paragraph with only $461 of cash outside trust. The pending deal is the February 2, 2026 Business Combination Agreement with PrimeGen US, Inc.

What changed: Limited Power of Attorney filed as Exhibits A and B to a Schedule 13G, formally designating Takahiro Katsura, Shuji Matsuura, and Adam Hopkins to execute and submit Form 13G reports on behalf of Mizuho Financial Group, Inc., Mizuho Bank, Ltd., Mizuho Americas LLC, and Mizuho Securities USA LLC. Nothing altered regarding redemption deadlines, trust mechanics, extension procedures, deal progress, or sponsor conduct. The document records only an internal corporate authorization for regulatory filings and contains no operational updates for DT Cloud Star Acquisition Corp. Why it matters: Executed on 5-14-2026 by Shuji Matsuura and Adam Hopkins, the instrument serves exclusively as a routine compliance exhibit to satisfy Securities Exchange Act of 1934 Section 13(d) and 13(g) reporting requirements. It makes no claims about customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel beyond the named officers and subsidiary addresses in Tokyo, Japan, and New York, NY. Consequently, it has no substantive impact on shareholder redemption rights, trust accounting, or target acquisition timelines.

What changed: Quarterly report (Form 10-Q) for the period ending March 31, 2026. The SPAC entered into a Business Combination Agreement (BCA) on February 2, 2026, with PrimeGen US, Inc., and extended its combination deadline to October 26, 2026. Net loss for the quarter was $110,289, compared to net income of $630,284 in the prior-year quarter. As of March 31, 2026, the trust held $18,259,482 ($11.05 per share), down from $69 million at IPO due to redemptions of 5,247,491 shares. The company received a Nasdaq deficiency notice on April 6, 2026 for falling below the minimum 400 public shareholders. Why it matters: The filing confirms a signed business combination agreement with PrimeGen US (enterprise value ~$1.49 billion), a substantial trust value relative to the small remaining public float ($11.05/share vs. IPO price of $10.00), and a significant liquidity concern (negative working capital of $854,550, only $1,656 cash on hand). Nasdaq non-compliance adds execution risk. The sponsor continues to fund extensions ($225,000 in Q1 2026) and has extended the deadline to Oct. 26, 2026. The large trust value per share and non-redeeming public holders receiving additional warrants are positive for holders who stay in.

What changed: A Form 8-K current report filed under Item 5.02 to disclose the departure of a corporate director. According to the filing, Dr. Xunyong Zhou resigned from Director of DT Cloud Star Acquisition Corporation on April 7, 2026. The report, executed by Chief Executive Officer Sam Zheng Sun on April 10, 2026, states the resignation 'was not the result of any disagreement between him and the Company, the Board of Directors, or any committee of the Board of Directors on any matter.' The registrant identifies itself as a Cayman Islands entity classified under SIC 6770, with its principal office at Office 51, 10 Fl, 31 Hudson Yards, New York, NY 10001. Why it matters: This departure reduces the board's size ahead of the scheduled redemption window without identifying a successor, which may affect quorum availability and sponsor oversight while the SPAC remains in SEARCHING status. By explicitly attributing the exit to zero disagreement, the company aims to neutralize investor speculation concerning governance disputes, executive instability, or impending trust account erosion. The filing contains no disclosures regarding target acquisition progress, business combination negotiations, extension voting procedures, or the per-share trust balance, leaving all associated mechanics unchanged from prior filings.

What changed: SEC Form 8-K filing under Item 3.01, documenting a Nasdaq Deficiency Letter for failing to satisfy Listing Rule 5450(a)(2) (Minimum Public Holders Rule). As stated in the filing, Nasdaq’s Listing Qualifications Staff issued a Deficiency Letter on April 6, 2026, citing a March 27, 2026 shareholder analysis showing non-compliance with the 400 total holder threshold. According to the notice, the company has 45 calendar days until May 21, 2026, to submit a compliance plan. Nasdaq may grant an extension of up to 180 calendar days from the letter date upon plan acceptance, though denial permits an appeal to a Hearings Panel or a potential transfer to the Nasdaq Capital Market. Company leadership, signed by Chief Executive Officer Sam Zheng Sun, confirmed active exploration of compliance options while disclaiming any assurance of success or ongoing Nasdaq adherence. This report contains no updates to redemption schedules, trust distributions, deSPAC target status, or sponsor activity. Why it matters: A sustained deficiency below the 400-public-holder floor exposes the issuer to delisting, which historically compresses liquidity, elevates compliance costs, and disrupts the capital markets infrastructure required to close a business combination before the existing redemption deadline. Without an accepted curing plan by May 21, 2026, or a secured 180-day extension, forced relocation to a less liquid venue or mandatory dissolution could immediately impair investor exit pathways and alter the economics tied to the prevailing trust reserve per share.

What changed: DT Cloud Star Acquisition Corporation's annual report on Form 10-K for the fiscal year ended December 31, 2025 — a shell-company periodic report, not a merger agreement or proxy statement. The 10-K discloses that on February 2, 2026, DT Cloud Star entered a Business Combination Agreement with PrimeGen US, Inc. and related parties, involving a redomestication merger and acquisition merger; the deal was not consummated as of the financial statement issuance date. It also shows major trust-account mechanics: the trust balance fell from $70,456,287 at December 31, 2024 to $17,876,466 at December 31, 2025 after 5,247,491 public shares were tendered for redemption; redeemable ordinary shares fell from 6,900,000 to 1,652,509, with a December 31, 2025 redemption price of $10.82 per share. The deadline was extended to October 26, 2026 by amending the trust agreement and depositing $75,000 per month for one-month extensions; $150,000 of extension contributions were recorded as of December 31, 2025. Outside the trust, the company had only $461 of cash and a $361,245 working capital deficit, and the auditor report includes substantial doubt about going concern. The sponsor's working capital loan note was terminated on July 29, 2025 with $nil outstanding, and extension notes were issued to the sponsor. Why it matters: For investors tracking redemption deadlines and deal progress, this filing confirms DT Cloud Star has a signed target — PrimeGen US, Inc. — with a stated Purchase Price of $1,489,800,000 before warrant/option adjustments, plus a non-redemption warrant mechanism for 1,931,900 shares intended to reduce redemptions. But the deal remains subject to shareholder approval and customary closing conditions, and the company has already absorbed heavy redemptions, leaving the trust at $17,876,466 across 1,652,509 redeemable shares at $10.82 per share as of year-end. Liquidity is extremely tight outside trust, and the company warns it may liquidate if no business combination closes by October 26, 2026 unless further extended. The BCA, redemption dynamics, sponsor extension financing, and going concern are the key items to watch.

What changed: A Form 8-K Current Report (Item 8.01 Other Events) serving as a statutory notice of a trust account extension payment and revised business combination deadline. According to the registrant's own statement, on March 16, 2026, DT Cloud Star Acquisition Corporation deposited an extension payment of $150,000 into the trust account. The filing asserts this deposit extends the window to complete an initial business combination by two months, establishing a new hard deadline of March 26, 2026. The disclosure is executed and attested by Chief Executive Officer Sam Zheng Sun on March 18, 2026. Why it matters: The filing directly overhauls the redemption and liquidation calendar, collapsing the remaining execution window to roughly ten days before the March 26, 2026 cutoff. This compression forces immediate shareholder decisions regarding redemption versus continued trust exposure. The $150,000 contribution mechanically increases the aggregate trust balance, confirming sponsor continuation funding. However, the administrative delay in publishing the extension—filing the report eight days after the new deadline had already commenced—signals acute operational constraints and suggests management is either racing to finalize a deal under duress or preparing for rapid trust wind-down, heavily weighting near-term valuation and settlement risk.

What changed: Routine Compliance Exhibit (Joint Filing Agreement appended to a Schedule 13G/A amendment). The filing records a procedural consent among four affiliated reporting persons—Westchester Capital Management, LLC; Westchester Capital Partners, LLC; Virtus Investment Advisers, LLC; and The Merger Fund—to jointly file Schedule 13G and all future amendments regarding DT Cloud Star Acquisition Corporation Ordinary Shares under Rule 13d-1(k). Mechanically, this agreement does not alter the holder’s beneficial ownership percentage, acquisition price, acquisition date, sole or shared voting/investment power, or prior disclosure positions. Consequently, the SPAC’s redemption parameters, current SEARCHING status, outstanding trust balance, October 26, 2026 termination deadline, and sponsor conduct remain entirely unchanged and unprompted by this submission. Why it matters: The exhibit contains no strategic, operational, or financial disclosures regarding customers, revenue, market size, technology, partnerships, litigation, or personnel. It consists solely of execution blocks dated February 13, 2026, signed by CaSaundra Wu (Chief Compliance Officer for both Westchester entities), Chetram Persaud (Chief Compliance Officer for Virtus), and Daphne Chisolm (Vice President, Counsel and Assistant Secretary for The Merger Fund) to satisfy SEC joint-filing convenience rules. For investors tracking redemption calendars or extension dynamics, this document represents administrative housekeeping that preserves existing institutional voting alignments without introducing new cash calls, waiver requests, or target-search updates. Continued scrutiny of the accompanying 13G/A page for actual percentage movement or amendment flags remains necessary.

What changed: A routine compliance exhibit: a Schedule 13G/A beneficial ownership report filed by Barclays PLC. The filing text identifies Barclays PLC as the reporting holder of a Schedule 13G/A amendment, but discloses no share quantities, transaction activities, or statements addressing the stated deadline, the reported trust/per-share value, extension motions, target identification, or sponsor conduct. Why it matters: Schedule 13G/A amendments allow investors to track institutional equity positioning relative to a SPAC’s search window and potential shareholder actions, yet because Barclays PLC did not attach numerical holdings or strategic declarations in the excerpt, the filing yields no direct guidance on redemption thresholds, trust maintenance, or deal execution timelines.(flagged for human review)